跳到正文
登录

公司

Tenax Therapeutics, Inc.

打开结构图

Tenax Therapeutics, Inc. 的结构

Tenax Therapeutics, Inc.

公司

4 个关联
约束监管与敞口
自有产品与技术
关系出现时间2026
Tenax Therapeutics, Inc.公司 · 4 个关联
第 1 层

自有产品与技术2

约束监管与敞口2

在关系网络中的位置

第 10404 位,共 118934 个前 9%本周上升 6943 位

3 条直接关系

所在群组共 990 个紧密关联的对象,核心是

本周新增关系

按有证据的公开关系计算,每天更新。

关系

箭头表示关系方向,可按业务类别筛选。

  • Tenax Therapeutics, Inc.使用 →levosimendan
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-06 10:21
      Tenax's prioritized product candidate is levosimendan, which the Company evaluated through, *inter alia*, its Phase 3 LEVEL study of oral levosimendan, or TNX-103, in pulmonary hypertension in heart failure with preserved ejection fraction ("PH-HRpEF").
      查看来源
    • 公司披露PR Newswire news releases2026-11-06 10:21
      Tenax conducted and completed its Phase 2 HELP study of levosimendan
      查看来源
    • 公司披露PR Newswire news releases2026-10-30 21:06
      Its prioritized product candidate is levosimendan, which it evaluated in the Phase 3 LEVEL study as TNX-103.
      查看来源
    • 公司披露PR Newswire news releases2026-10-30 21:06
      which it evaluated in the Phase 3 LEVEL study as TNX-103.
      查看来源
    • 公司披露PR Newswire news releases2026-10-28 10:25
      Tenax's prioritized product candidate is levosimendan
      查看来源
  • Tenax Therapeutics, Inc.使用 →TNX-103
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-10-28 10:25
      its Phase 3 LEVEL study of oral levosimendan, or TNX-103
      查看来源
  • Tenax Therapeutics, Inc.制造 →TNX-103
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-09 22:25
      Tenax Therapeutics is a development-stage pharmaceutical company that develops novel cardiopulmonary therapies in the United States.
      查看来源
    • 公司披露PR Newswire news releases2026-11-09 16:32
      Tenax revealed that its Phase 3 LEVEL trial of TNX-103 failed to meet its primary and secondary endpoints.
      查看来源
  • Tenax Therapeutics, Inc.位于 →San Diego
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-09 22:25
      SAN DIEGO, Nov. 9, 2026 /PRNewswire/ --
      查看来源
  • Tenax Therapeutics, Inc.受监管于 →Securities Exchange Act of 1934
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-09 22:25
      the *Tenax Therapeutics* class action lawsuit charges Tenax Therapeutics as well as certain of Tenax Therapeutics' top current and former executives with violations of the Securities Exchange Act of 1934.
      查看来源
  • Tenax Therapeutics, Inc.供应给 →TNX-103
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-09 22:25
      Tenax Therapeutics announced that the U.S. Food and Drug Administration had cleared Tenax Therapeutics' Investigational New Drug Application for TNX-103 (levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction, and that accordi…
      查看来源
  • Tenax Therapeutics, Inc.产出 →Cardiopulmonary therapies
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-16 22:49
      develops novel cardiopulmonary therapies
      查看来源
  • Tenax Therapeutics, Inc.属于 →pharmaceutical industry
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-16 22:49
      is a development-stage pharmaceutical company
      查看来源

显示第 1 至 8 条,共 9 条

结论

结合来源阅读结论,展开条目查看证据。

事实证据 2

Tenax is a development-stage pharmaceutical company focused on novel cardiopulmonary therapies.

PR Newswire news releases · 2026-11-17 09:16

查看证据
  • 公司披露PR Newswire news releases2026-11-17 09:16
    Tenax is a development-stage pharmaceutical company focused on novel cardiopulmonary therapies.
    查看来源
  • 公司披露PR Newswire news releases2026-11-06 10:21
    Tenax is a Phase 3, development-stage pharmaceutical company that develops novel cardiopulmonary therapies.
    查看来源
事实证据 2
tickerTENX

Tenax Therapeutics, Inc. (NASDAQ: TENX) securities

PR Newswire news releases · 2026-11-17 09:16

查看证据
  • 公司披露PR Newswire news releases2026-11-17 09:16
    Tenax Therapeutics, Inc. (NASDAQ: TENX) securities
    查看来源
  • 公司披露PR Newswire news releases2026-11-02 03:30
    Tenax Therapeutics, Inc. (NASDAQ: TENX)
    查看来源
事实证据 1

is a development-stage pharmaceutical company

PR Newswire news releases · 2026-11-16 22:49

查看证据
  • 公司披露PR Newswire news releases2026-11-16 22:49
    is a development-stage pharmaceutical company
    查看来源
事实证据 1

develops novel cardiopulmonary therapies

PR Newswire news releases · 2026-11-16 22:49

查看证据
  • 公司披露PR Newswire news releases2026-11-16 22:49
    develops novel cardiopulmonary therapies
    查看来源
事实证据 1
closing price1.38 $ per share

to close at approximately $1.38 per share on August 10, 2026.

PR Newswire news releases · 2026-11-16 22:49

查看证据
  • 公司披露PR Newswire news releases2026-11-16 22:49
    to close at approximately $1.38 per share on August 10, 2026.
    查看来源
事实证据 1
供应给TNX-103

Tenax Therapeutics announced that the U.S. Food and Drug Administration had cleared Tenax Therapeutics' Investigational New Drug Application for TNX-103 (levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction, and that accordi…

PR Newswire news releases · 2026-11-09 22:25

查看证据
  • 公司披露PR Newswire news releases2026-11-09 22:25
    Tenax Therapeutics announced that the U.S. Food and Drug Administration had cleared Tenax Therapeutics' Investigational New Drug Application for TNX-103 (levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction, and that accordi…
    查看来源

显示第 1 至 6 条,共 26 条

市场与估值

估值数据需要 Pro 或 Research。

升级到 Pro 解锁

推荐一个值得监测的页面

这家公司有哪些页面值得盯着,比如价格、更新日志、条款或招聘页?推荐给我们。每条推荐都有人看;收录后,这个页面会为所有读者一起监测,并且只有连续两次抓取一致才算一次变化。

登录后推荐页面

暂无: 公司信号 · 财务数据 · 披露文件 · 据点 · 业绩指引